SCHEMBL20965291

SCHEMBL20965291

Cc1noc(CSc2ccccc2C(=O)N2CCN(c3cccc(C(F)(F)F)c3)CC2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.55
NPC1 O15118 1/20 0.55
KMT2A Q03164 3/20 0.55
MEN1 O00255 2/20 0.55
MAPK1 P28482 2/20 0.55
TSHR P16473 7/20 0.54
LMNA P02545 6/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
ALDH1A1 P00352 2/20 0.54
MAPT P10636 5/20 0.51
HTT P42858 4/20 0.51
POLB P06746 1/20 0.51
GAA P10253 1/20 0.51
ATM Q13315 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
TDP1 Q9NUW8 1/20 0.47
THRB P10828 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20964937 0.89 LMNA (0.58) L3MBTL1NPC1KMT2AMEN1MAPK1
SCHEMBL20964539 0.85 TSHR (0.77) L3MBTL1NPC1KMT2AMEN1MAPK1
SCHEMBL30428560 0.85 TSHR (0.77) L3MBTL1NPC1KMT2AMEN1MAPK1
SCHEMBL20965398 0.84 LMNA (0.57) L3MBTL1KMT2AMEN1MAPK1TSHR
SCHEMBL19744712 0.79 MEN1 (0.56) L3MBTL1NPC1KMT2AMEN1MAPK1
SCHEMBL20964557 0.79 LMNA (0.67) KMT2AMEN1TSHRLMNASMN1; SMN2
SCHEMBL25057031 0.79 LMNA (0.76) L3MBTL1NPC1KMT2AMEN1MAPK1
SCHEMBL25057093 0.78 MEN1 (0.53) L3MBTL1NPC1KMT2AMEN1MAPK1
SCHEMBL20965436 0.77 L3MBTL1 (0.63) L3MBTL1KMT2AMEN1TSHRLMNA
SCHEMBL20964555 0.76 ALDH1A1 (0.49) L3MBTL1KMT2AMEN1MAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-12-01 US disclosed
US-20190127361-A1 Therapeutic Compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127361-A1 Therapeutic Compounds SDHA, SLC10A1, SERPINC1 L3MBTL1 4755/4885NPC1 11/4885KMT2A 4728/4885
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents SERPINC1, F12, RPL35 L3MBTL1 4517/4885NPC1 2196/4885KMT2A 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.